Rekombinanter CD4 (Clenoliximab Biosimilar) Antikörper
-
- Target
- CD4 (Clenoliximab Biosimilar)
- Antikörpertyp
- Recombinant Antibody
- Reaktivität
- Human, Schimpanse
-
Wirt
-
Human
-
Klonalität
- Monoklonal
-
Konjugat
- Unkonjugiert
- Applikation
- Surface Plasmon Resonance (SPR), Blocking Reagent (BR), ELISA, Flow Cytometry (FACS), Immunohistochemistry (IHC)
- Verwendungszweck
- Anti-CD4 [CE9.1 (Clenoliximab)], Human IgG4, lambda
- Spezifität
- The antibody binds to human CD4 with a Kd of 1.0 nM and an ED50 of 0.2 μg/mL.
- Kreuzreaktivität
- Schimpanse
- Produktmerkmale
-
Original Species of Ab: Human
Original Format of Ab: IgG4 (primatized)
- Aufreinigung
- Protein A affinity purified
- Reinheit
- > 98 % as determined by SDS-PAGE
- Endotoxin-Niveau
- Endotoxin is < 1.0 EU/mg as determined by the LAL method
- Immunogen
- Domain 1 of human CD4.
- Klon
- CE9-1
- Isotyp
- IgG4 lambda
-
anti-CD4 (Clenoliximab Biosimilar) antibody
Reaktivität: Human, Schimpanse SPR, BR, ELISA, FACS, IHC Wirt: Kaninchen Chimeric CE9-1 unconjugated Recombinant Antibody
-
- Applikationshinweise
- The antibody binds specifically to CD4, a molecule which is part of the immunolgobulin super-family, expressed on the surface of helper T cells. The CD4 Molecule acts as a co-receptor in the activation of T cells, aiding the interaction between the TCR and MHC II of the antigen-presenting cell. The antibody is classified as "primatized", as the variable regions of the light and heavy chains are obtained from primates, while the lamda light chain and γ4 heavy chain constant domains are human. The antibody was engineered from the primatized IgG1 monoclonal antibody Keliximab by substituting two key residues. The role of the antibody as an immunosuppressor has been tested in vivo, by intravenous administration in chimpanzees and human volunteers. The antibody reached Phase II clinical trials with Biogen-Idec.
- Kommentare
-
NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This reformatted human antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques.
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Konzentration
- 1 mg/mL
- Buffer
- PBS with 0.02 % Proclin 300.
- Konservierungsmittel
- ProClin
- Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Lagerung
- 4 °C,-20 °C
- Informationen zur Lagerung
- Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
-
- Target
- CD4 (Clenoliximab Biosimilar)
- Substanzklasse
- Biosimilar
- Hintergrund
- P55, T cell surface antign T4/Leu-3.
- UniProt
- P01730
-
